Top Markets
#1 DogBull DogBull +108.19%
#2 Siacoin Siacoin +43.86%
#3 The Bitcoin Bull The Bitcoin Bull +29.88%
#4 Ontology Gas Ontology Gas +16.64%
#5 Akedo Akedo +13.53%
#6 UnifAI Network UnifAI Network +12.41%
#7 Cash Cat Cash Cat +11.73%
#8 Pons Pons +10.90%
#9 ADO Protocol ADO Protocol +9.99%
#10 Cryptopia Cryptopia +9.96%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Kedudukan dalam Saham #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Harga Saham
$16.85
Disegerakkan terakhir: 2023-07-07
Modal Pasaran
$393.50M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CH
Perdagangan VectivBio Holding AG (VECT)

Kategori

Healthcare
Hasil untuk VectivBio Holding AG (VECT)
Hasil pada Sep 2026 TTM: 0
Menurut laporan kewangan terkini daripada VectivBio Holding AG, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi VectivBio Holding AG dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH